An international survey of cytomegalovirus management practices in lung transplantation

Transplantation

Volumn 90, Issue 6, 2010, Pages 672-676

  Zuk, Dalyce M ^a,b   Humar, Atul ^a   Weinkauf, Justin G ^a   Lien, Dale C ^a   Nador, Roland G ^a   Kumar, Deepali ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Ganciclovir; Prophylaxis; Viral therapy

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; ANTIVIRUS AGENT;

ARTICLE; CYTOMEGALOVIRUS INFECTION; HUMAN; INFECTION PREVENTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; VIRUS DETECTION; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG COMBINATION; ELECTRONIC MEDICAL RECORD; GENETICS; HEALTH SURVEY; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; GANCICLOVIR; HEALTH SURVEYS; HUMANS; INTERNATIONALITY; LUNG TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 77957280871     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ea3955     Document Type: Article

References (22)

1. Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008; 41: 237.
2. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006; 16: 281.
3. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
4. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82: 30.
5. Singh N. Preemptive therapy versus universal prophylaxis with ganci-clovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32: 742.
6. Torre-Cisneros J, Madueno JA, Herrero C, et al. Pre-emptive oral gan-ciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 2002; 8: 773.
7. Avery RK, Adal KA, Longworth DL, et al. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalo-virus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26: 763.
8. Puius YA, Snydman DR. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: Current approach and future challenges. Curr Opin Infect Dis 2007; 20: 419.
9. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
10. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831.
11. Opelz G, Dohler B, Ruhenstoth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
12. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635.
13. Levitsky J, Singh N, Wagneer MM, et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8: 158.
14. Humar A, Snydman D; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S78.
15. Danziger-Isakov LA, Faro A, Sweet S, et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight pediatric lung transplant programs. Pediatric Transplant 2003; 7:469.
16. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of antifungal management in lung transplantation. J Heart Lung Transplant 2004; 23: 1376.
17. Humar A, Lebranchu Y, Vincenti F, et al. The IMPACT study: Valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease. AmJ Transplant 2009; 9 (suppl 2): 248.
18. Humar A, Paya C, Pescovitz MD, et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R\solid organ transplant recipients. Am J Transplant 2004; 4: 644.
19. Bordils A, Sanchez Plumed J, Ramox D, et al. Comparison of quantitative PCR and antigenemia in cytomegalovirus infection in renal transplant recipients. Transplant Proc 2005; 37: 3756.
20. Kruger RM, Paranjothi S, Storch GA, et al. Impact of prophylaxis with CytoGam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003; 22: 754.
21. ISHLT. The registry of the international society of heart and lung transplantation: Twenty fifth annual report. J Heart Lung Transplant 2008; 27: 937
22. United Network for Organ Sharing [Online]. Available at: http://www. unos.org/members/directory.asp. Accessed April 23,2009.